Guardant Health price target raised to $70 from $60 at Stifel

Stifel raised the firm’s price target on Guardant Health (GH) to $70 from $60 and keeps a Buy rating on the shares. The company’s successful analyst day reminds investors why Guardant is “a market leader with a solid runway ahead,” says the analyst, who cites a combination of helpful information on the company’s improvement efforts and a financial update that “may not have yielded the ’25 guidance raise that some were looking for, but signaled strength and momentum on several fronts.”